May 17, 2019

Pharma's bad behavior is causing its own problems

Illustration: Rebecca Zisser/Axios

The pharmaceutical industry is under fire in the public eye, in Congress and in the courts. And it mostly brought this on itself — through price hikes, allegedly anticompetitive behavior and aggressive opioid marketing.

The big picture: There's a real debate to be had about the value of new, innovative, sometimes life-saving drugs. But the industry has clouded its own argument, and weakened its own political standing, through a slew of bad behavior.

Driving the news: New, scientifically advanced therapies come with eye-popping prices. One product may be about to come to market with a $2 million price tag. But it's also a medical breakthrough, curing a disease that often kills babies before their second birthday.

  • While the industry argues those treatments are worth the cost, its critics point to a series of price hikes on products that have been around for decades — like insulin and the EpiPen.

Other business practices are also under scrutiny.

  • Congress is considering changes to patent law, saying brand-name manufacturers "game" the system to unfairly keep generics at bay. Brands also deny generics the product samples they need to create their products, critics argue.
  • Legal settlements that keep generics off the market are under the microscope.
  • 20 generic drug companies were recently sued for allegedly colluding to either maintain drug prices or raise them by as much as 1,000%.

At the same time, drugmakers including Purdue Pharma and Johnson & Johnson are facing high-profile, multi-billion-dollar lawsuits over their roles in the opioid crisis.

“There’s a lot of money in health care and...the rules are sufficiently vague, and the opportunities are sufficiently great, that I think a lot of people are willing to take what appears to them as minimal risk for a potentially big payoff," the American Enterprise Institute's Joe Antos said.

The other side: Pharma argues that some controversial behaviors — like the steady increase in prices — are a result of drug middlemen's practices, and that they're necessary to fund the research that will lead to more breakthrough therapies.

  • "Is this industry more prone to fraud, or is it just more scrutinized?" former FDA Commissioner Scott Gottlieb asked.
  • "Most people working in the pharmaceutical industry are there to help improve patient lives. However, we have built a system where gaming is possible, partly due to a lack of transparency," said Vanderbilt's Stacie Dusetzina.
  • Holly Campbell, a spokeswoman for PhRMA — the main trade group representing the industry — pointed out that drug price growth has slowed down in recent years, and that as deductibles and other forms of cost sharing rise rise, patients end up shouldering more of the cost of their medicines.
  • With the rise of science that "would have been considered science fiction ten years ago," the industry is "advocating for new ways to pay for medicines so that our payment system keeps up with the pace of innovation," Campbell said.

The bottom line: "I don't think we should expect the industry to be a moral actor when everything we do in U.S. policy regarding pharma focuses...purely on money and financial incentives," said Memorial Sloan-Kettering Cancer Center's Peter Bach.

  • "As a matter of policy, we the people believe the industry should respond almost solely to financial risks and rewards, and so they do," he added.

Go deeper

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 1:30 a.m. ET: 5,695,155 — Total deaths: 355,688 — Total recoveries — 2,351,177Map.
  2. U.S.: Total confirmed cases as of 1:30 a.m. ET: 1,699,933 — Total deaths: 100,442 — Total recoveries: 391,508 — Total tested: 15,192,481Map.
  3. Public health: CDC issues guidelines for reopening officesFauci says data is "really quite evident" against hydroxychloroquine.
  4. States: California hospitals strained by patients in MexicoTexas Supreme Court blocks mail-in expansion to state voters.
  5. Business: MGM plans to reopen major Las Vegas resorts in June — African American business owners have seen less relief from PPP, Goldman Sachs says.
  6. Tech: AI will help in the pandemic — but it might not be in time for this one.
  7. World: EU proposes a massive pandemic rescue package.
  8. 1 🎶 thing: Local music venues get rocked by coronavirus.
  9. 🎧 Podcast: Trump vs. Twitter ... vs. Trump.
  10. What should I do? When you can be around others after contracting the coronavirus — Traveling, asthma, dishes, disinfectants and being contagiousMasks, lending books and self-isolatingExercise, laundry, what counts as soap — Pets, moving and personal healthAnswers about the virus from Axios expertsWhat to know about social distancingHow to minimize your risk.
  11. Other resources: CDC on how to avoid the virus, what to do if you get it, the right mask to wear.

Subscribe to Mike Allen's Axios AM to follow our coronavirus coverage each morning from your inbox.

Updated 13 mins ago - Politics & Policy

Minneapolis unrest as hundreds protest death of George Floyd

Protesters and police clash during demonstration on Wednesday over the death of George Floyd in custody outside the Third Police Precinct. Photo: Kerem Yucel/AFP via Getty Images

Minneapolis police clashed for a second night with protesters demonstrating the death of George Floyd, an African American man who died in police custody.

The latest: Minnesota Gov. Tim Walz tweeted late Wednesday that the situation where the clashes were taking place was "extremely dangerous" as he urged people to leave the area. There were multiple news reports of police firing tear gas at protesters and of some people looting a Target store.

Blue Cross Blue Shield insurers sue CVS, alleging drug pricing fraud

Photo: John Lamparski/SOPA Images/LightRocket via Getty Images

Six Blue Cross Blue Shield insurers have sued CVS Health, alleging the pharmacy chain overcharged them based on "artificially inflated prices" for generic drugs and concealed the true cash prices of those drugs.

The big picture: CVS has faced legal scrutiny over its cash discount programs since 2015, and this lawsuit adds big names to a mounting problem.